Skip to main content
SpringerLink
Log in

Antibiotics, Antiretroviral, Corticosteroids, Other Therapies Against SARS-CoV-2

  • Chapter
  • First Online:
COVID-19 Critical and Intensive Care Medicine Essentials

  • 434 Accesses

Abstract

Pharmacological treatment for COVID-19 is still exclusively supportive [1]. Drugs have been tested based on the pathogenesis events, particularly considering the potential impact on? (1) the viral infection and replication cycle (early phase); and (2) the inflammatory response phase marked by a cytokine storm that leads to tissue damage [2, 3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Robba C, Battaglini D, Ball L, Patroniti N, Loconte M, Brunetti I, et al. Distinct phenotypes require distinct respiratory management strategies in severe COVID-19. Respir Physiol Neurobiol. 2020;279:103455.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Battaglini D, Robba C, Ball L, Cruz FF, Silva PL, Pelosi P, et al. Emerging therapies for COVID-19 pneumonia. Expert Opin Investig Drugs. 2020;29:633–7.

    Article  CAS  PubMed  Google Scholar 

  3. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Strathdee SA, Davies SC, Marcelin JR. Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election. Lancet. 2020;396:1050–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. World Health Organization. Clinical management of COVID-19: interim guidance, 27 May 2020. Geneva: World Health Organization; 2020.

    Google Scholar 

  7. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61–111.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Sieswerda E, de Boer MGJ, Bonten MMJ, Boersma WG, Jonkers RE, Aleva RM, et al. Recommendations for antibacterial therapy in adults with COVID-19—an evidence based guideline. Clin Microbiol Infect. 2021;27:61–6.

    Article  CAS  PubMed  Google Scholar 

  9. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45–67.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Wiersinga WJ, Bonten MJ, Boersma WG, Jonkers RE, Aleva RM, Kullberg BJ, et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). Neth J Med. 2018;76:4–13.

    CAS  PubMed  Google Scholar 

  11. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323:1824–36.

    Article  CAS  PubMed  Google Scholar 

  12. Mody V, Ho J, Wills S, Mawri A, Lawson L, Ebert MCCJC, et al. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun Biol. 2021;4:93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19:149–50.

    Article  PubMed  CAS  Google Scholar 

  14. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9:e00221–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9:eaal3653.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048–57.

    Article  CAS  PubMed  Google Scholar 

  17. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383:1827–37.

    Article  CAS  PubMed  Google Scholar 

  18. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med. 2020;383:1813–26.

    Article  CAS  PubMed  Google Scholar 

  19. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo A-M, Preziosi M-P, Sathiyamoorthy V, et al. Repurposed antiviral drugs for Covid-19—Interim WHO Solidarity Trial results. N Engl J Med. 2021;384:497–511.

    Article  Google Scholar 

  20. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. 2021;384:693–704.

    Article  Google Scholar 

  21. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473–4.

    Article  CAS  PubMed  Google Scholar 

  22. Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020;2:e428–36.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Ahmed MH, Hassan A. Dexamethasone for the treatment of coronavirus disease (COVID-19): a review. SN Compr Clin Med. 2020;2(12):2637–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med. 2020;48:e440–69.

    Article  CAS  PubMed  Google Scholar 

  25. Mattos-Silva P, Felix NS, Silva PL, Robba C, Battaglini D, Pelosi P, et al. Pros and cons of corticosteroid therapy for COVID-19 patients. Respir Physiol Neurobiol. 2020;280:103492.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct Target Ther. 2020;5:57.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Zhu J, Pang J, Ji P, Zhong Z, Li H, Li B, et al. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis. J Med Virol. 2021;93:35–7.

    Article  CAS  PubMed  Google Scholar 

  28. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146:128–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020;92:2283–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021;181:41–51.

    Article  CAS  PubMed  Google Scholar 

  31. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117:10970–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384:20–30.

    Article  CAS  PubMed  Google Scholar 

  33. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/. Accessed 23 Feb 2021.

  34. Li N, Hua J. Interactions between mesenchymal stem cells and the immune system. Cell Mol Life Sci. 2017;74:2345–60.

    Article  CAS  PubMed  Google Scholar 

  35. Shetty AK. Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia. Aging Dis. 2020;11:462–4.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Uzunova K, Filipova E, Pavlova V, Vekov T. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomed Pharmacother. 2020;131:110668.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Moscona A. Oseltamivir resistance—disabling our influenza defenses. N Engl J Med. 2005;353:2633–6.

    Article  CAS  PubMed  Google Scholar 

  38. Chow EJ, Doyle JD, Uyeki TM. Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit Care. 2019;23:214.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol. 2017;93:449–63.

    Article  CAS  Google Scholar 

  40. Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018;153:85–94.

    Article  CAS  PubMed  Google Scholar 

  41. Satarker S, Ahuja T, Banerjee M, Dogra S, Agarwal T, Nampoothiri M. Hydroxychloroquine in COVID-19: potential mechanism of action against SARS-CoV-2. Curr Pharmacol Rep. 2020;6(5):203–11. https://doi.org/10.1007/s40495-020-00231-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Yang SN, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res. 2020;177:104760.

    Article  CAS  PubMed  Google Scholar 

  44. Lehrer S, Rheinstein PH. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. In Vivo. 2020;34:3023–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Centro de Ciências da Saúde, Ilha do Fundão, Rio de Janeiro, RJ, Brazil

    Dayene de Assis Fernandes Caldeira, Patricia Rieken Macedo Rocco & Fernanda Ferreira Cruz

Authors
  1. Dayene de Assis Fernandes Caldeira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia Rieken Macedo Rocco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fernanda Ferreira Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fernanda Ferreira Cruz .

Editor information

Editors and Affiliations

  1. Anesthesia and Critical Care Unit, Ospedale San Martino, Genova, Italy

    Denise Battaglini

  2. Anesthesia and Critical Care, Ospedale San Martino, Genoa, Italy

    Paolo Pelosi

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

de Assis Fernandes Caldeira, D., Rocco, P.R.M., Cruz, F.F. (2022). Antibiotics, Antiretroviral, Corticosteroids, Other Therapies Against SARS-CoV-2. In: Battaglini, D., Pelosi, P. (eds) COVID-19 Critical and Intensive Care Medicine Essentials. Springer, Cham. https://doi.org/10.1007/978-3-030-94992-1_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-94992-1_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-94991-4

  • Online ISBN: 978-3-030-94992-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation